Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)

NCT04620330 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.

NCT NCT04620330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04620330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Lead sponsor
Verastem, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2020
Completion date
December 12, 2023
Enrollment
90 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

kras activating mutation, non small cell lung cancer